CLINICAL TRIALS PROFILE FOR ESTRADIOL VALERATE AND DIENOGEST
✉ Email this page to a colleague
All Clinical Trials for Estradiol Valerate And Dienogest
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00293059 ↗ | Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding | Completed | Bayer | Phase 3 | 2005-12-01 | The purpose of this study is to determine whether the study drug is safe and effective in the treatment of dysfunctional uterine bleeding. |
NCT00307801 ↗ | Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding | Completed | Bayer | Phase 3 | 2006-02-01 | The purpose of this study is to determine whether the study drug is safe and effective in the treatment of dysfunctional uterine bleeding. |
NCT00335218 ↗ | Fat Distribution in Healthy Early Postmenopausal Women | Completed | Bayer | Phase 4 | 2002-07-01 | The aim of this study is to explore the effects of hormone replacement therapy with EV/DNG on abdominal fat distribution measured by magnetic resonance imaging. |
NCT00764881 ↗ | Effects of SH T00658ID on Libido | Completed | Bayer | Phase 3 | 2009-01-01 | The aim of the study is to investigate whether women on oral contraceptives (OCs) suffering from acquired OC-associated female sexual dysfunction (FSD) for at least 3 months but no longer than one year will express the same level of sexual distress when taking SH T00658ID compared to Microgynon, the usual OC prescribed for women with OC-associated FSD. |
NCT00778609 ↗ | Effect of a New Oral Contraceptive Pill on Hormone Related Symptoms Such as Pelvic Pain and Headache | Completed | Bayer | Phase 3 | 2008-12-01 | The aim of the present study is to investigate whether women taking a new combined oral contraceptive pill (SH T00658ID, estradiol valerate/dienogest) experience fewer hormone withdrawal-associated symptoms such as pelvic pain or headache during their monthly cycle compared to a commonly used contraceptive pill (Microgynon). |
NCT00805415 ↗ | Ovulation Inhibition of Two 4-phasic Oral Contraceptive Regimens | Completed | Bayer | Phase 2 | 2003-03-01 | The aim of the study is to investigate the ovulation inhibition of two 4-phasic oral contraceptive regimens. |
NCT00941057 ↗ | Bioequivalence Study: 2 mg Estradiol Valerate (EV) and 3 mg Dienogest (DNG) Without and With Levomefolate Calcium | Completed | Bayer | Phase 1 | 2009-09-01 | Investigation of the bioequivalence (BE) of Estradiol Valerate (EV) and Dienogest (DNG) after administration of one film-coated tablet containing 2 mg Estradiol Valerate, 3 mg Dienogest and 0.451 mg Levomefolate calcium as compared to one film-coated tablet containing 2 mg Estradiol Valerate,3 mg Dienogest.Investigation of the bioequivalence of levomefolate calcium after administration of one film-coated tablet containing 2 mg Estradiol Valerate, 3 mg Dienogest and 0.451 mg Levomefolate calcium as compared to one film-coated tablet containing 0.451 mg levomefolate calcium |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Estradiol Valerate And Dienogest
Condition Name
Clinical Trial Locations for Estradiol Valerate And Dienogest
Trials by Country
Clinical Trial Progress for Estradiol Valerate And Dienogest
Clinical Trial Phase
Clinical Trial Sponsors for Estradiol Valerate And Dienogest
Sponsor Name